Navigation Links
DelMar Pharmaceuticals Fiscal 2014 Year End Results and Summary of Recent Developments
Date:8/29/2014

atient enrollment and expansion of certain cohorts during 2013. Partially offsetting these items were higher costs in the current period for protocol development as DelMar plans for registration-directed clinical trials with VAL-083. Decrease in general and administrative costs during the current period was largely due to a reduction in professional fees related to activities associated with the Company's reverse take-over and public listing that occurred during 2013.

"Non-cash expenses associated with stock options, shares or warrants issued for services or the changes in the derivative liability associated with certain warrants do not affect our working capital and are influenced by changes in the Company's share price," stated Mr. Bacha. "We are highlighting expenses net of such charges because this more accurately reflects the operating cash burn associated with our research, drug development and corporate activities. Full details are presented in our financial statements."

Subsequent to the fiscal year end, DelMar received additional funding through the exercise of warrants for cash. These additional moneys provide working capital sufficient to fund the Company's current operations through at least the end of December 2015.

About DelMar PharmaceuticalsDelMar Pharmaceuticals was founded in 2010 to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing modern targeted or biologic treatments. The Company's lead asset, VAL-083, is currently undergoing clinical trials in the United States as a potential treatment for recurrent glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. VAL-083 benefits from extensive clinical research sponsored by the U.S. National Cancer Institute (NCI) and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical an
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Novastem, a leader in regenerative medicine, ... its study for ischemic stroke at Clinica Santa ... strokes account for 87 percent of all stroke ... the study, entitled "Internal Research Protocol in Combination ... Cells and Intrathecal Administration of Neural Stem Cells ...
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... Dec. 24, 2014  Diplomat Pharmacy, Inc. (NYSE: ... is proud to announce Jennifer Hagerman , Pharm.D., ... will take office as the president of the Michigan ... ceremony will take place Feb. 28, 2015, at the ... at the Renaissance Center in Detroit, Michigan ...
Breaking Medicine Technology:Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 2Diplomat's senior director of education and quality to be inducted as 2015 president of the Michigan Pharmacists Association 3
... April 28, 2011 CardioFocus, Inc., developer of ... of Atrial Fibrillation (AF), convened international leaders in ... visualization to guide catheter ablation for the treatment ... day of the German Society for Cardiology Annual ...
... Inc. (OTC Bulletin Board: SCLR ) is pleased ... Pharma, Inc., will be presenting at Taglich Brothers 8th Annual ... will take place at the New York Athletic Club, New ... About SCOLR Pharma: Based in ...
Cached Medicine Technology:International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter 2International Leaders in Electrophysiology Discuss Improving Atrial Fibrillation Treatment Using Novel Endoscopically Guided Laser Ablation Catheter 3
(Date:12/26/2014)... Parker & Sons, Inc. a reliable ... cooling and plumbing contractor services throughout Arizona announces ... 2014 with regard to air-conditioning systems. Residential and ... for its incredibly hot summers. Working with an ... details of a wide variety of systems made ...
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... 26, 2014 This is a professional ... global Sterilizers industry with a focus on the Chinese ... status of the Sterilizers manufacturers and is a valuable ... interested in the industry. This report provides a basic ... manufacturing technology. In this part, the report presents the ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... The report “Nintedanib (Colorectal Cancer) ... on the current treatment landscape, unmet needs, current ... market. Stivarga is a drug which is used ... Boehringer Ingelheim is developing nintedanib (BIBF-1120), an orally ... CRC in the US, Europe, and Japan. The ...
Breaking Medicine News(10 mins):Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4
... Previous studies have shown that hepatitis C virus (HCV) ... than in whites. However, researchers demonstrate in this study, ... the American Association for the Study of Liver Diseases, ... recurrent HCV in the transplanted liver progresses faster in ...
... particular risk of their primary care physicians delaying diagnosis ... being presented at the American Society of Nephrology,s 42nd ... The findings suggest that educating practitioners about CKD ... to improvements in care to patients and savings in ...
... ,One Million Tests, World AIDS Day 2008 Campaign, AHF/Cambodia CARES ... 35,034 , PHNOM PENH, Cambodia, Oct. 31 As ... people for HIV in observance of the Testing ... will launch its inaugural testing effort during the annual Water ...
... suggests mortality rate may be linked to health-care inadequacies ... dementia are diagnosed with flu less often, have shorter ... die than those without dementia, says a U.S. study ... and older. , "The increased mortality of older patients ...
... , SAN FRANCISCO, Oct. 30 House speaker Nancy Pelosi ... Brown & Toland and a growing coalition of community groups ... epidemic. , Hepatitis B can cause liver cancer and ... Free campaign, of which Brown & Toland is a part, ...
... ... , ... 30, 2009 -- On Thursday this week, House Democratic leaders presented a new health care ... series of changes to accommodate lawmakers, concerns. In the Senate, Majority Leader Harry Reid (D-Nev.) ...
Cached Medicine News:Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 2Health News:African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C 3Health News:Women with chronic kidney disease more likely than men to go undiagnosed 2Health News:Cambodia: World AIDS Day HIV Campaign, 'Testing Millions,' to Again Launch During Cambodia's National Water Festival 2Health News:Flu Deaths Higher Among Seniors With Dementia 2Health News:Brown & Toland Supports Fight Against Hepatitis B 2Health News:NAMI Applauds Initial Review of The Affordable Health Care of America Act and Health Care Reform 2Health News:NAMI Applauds Initial Review of The Affordable Health Care of America Act and Health Care Reform 3
Operating microscope with motorized zoom and variable focus up to 405 mm....
Opmi Vario/S88 system surgical microscope. It is applicable for neurosurgery, spinal, ENT and P&R surgery....
DUALSWITCH-SHUNTSYSTEM for L-P-Derivation...
10 overall length 4.5 from bend 250 mm. 90...
Medicine Products: